Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:5-8
doi: 10.1161/CIRCULATIONAHA.106.670554
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maekawa, Y.
Right arrow Articles by Liu, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maekawa, Y.
Right arrow Articles by Liu, P. P.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Cardiomyopathy
Related Collections
Right arrow Other myocardial biology
Right arrow Other heart failure
Right arrow Animal models of human disease
Right arrow Heart failure - basic studies

(Circulation. 2007;115:5-8.)
© 2007 American Heart Association, Inc.


Editorial

Connecting the Missing Link Between Dilated Cardiomyopathy and Viral Myocarditis

Virus, Cytoskeleton, and Innate Immunity

Yuichiro Maekawa, MD, PhD; Maral Ouzounian, MD; M. Anne Opavsky, MD, PhD; Peter P. Liu, MD

From the Heart and Stroke/Richard Lewar Centre of Excellence, and Toronto General Research Institute, University Health Network, Toronto, Canada (Y.M., M.O., P.P.L.); the Hospital for Sick Children Research Institute, University of Toronto, Toronto, Canada (M.A.O.); and the Institute of Circulatory and Respiratory Health, Canadian Institutes of Health Research, Toronto and Ottawa, Canada (P.P.L.).

Correspondence to Peter Liu, MD, Institute of Circulatory and Respiratory Health, CIHR, NCSB 11–1266, Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, M5G 2C4, Canada. E-mail peter.liu@utoronto.ca


Key Words: Editorials • myocarditis • heart failure • cardiomyopathy • immune system • inflammation


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

Myocarditis classically refers to inflammation of the heart muscle. The mechanisms include host immune dysregulation and viral triggers such as coxsackievirus (CVB), adenovirus, parvovirus, and hepatitis C virus. The pathophysiology is initiated by viral proliferation in a susceptible host, inducing host immune response. The latter, when exuberant, leads to myocyte destruction and dilated cardiomyopathy.1,2 Clinically, patients with viral myocarditis will spontaneously recover in one third of cases, persist with the disease in one third, and deteriorate in another third of the cases.

Article p 94

Recent biopsy series in patients with dilated cardiomyopathy have revealed an interesting situation in which patients with symptoms of heart failure may show the presence of the viral genome alone, without any evidence of an overt inflammatory process.3 This raises the question of whether the virus can be directly responsible for the cardiomyopathy or whether it is merely an incidental bystander.

Viruses are exquisitely designed nanoparticles packaged with just the critical amount of genetic material to allow them to adapt to changing host and environmental conditions and to pass on genetic material to progeny. CVBs are single-stranded RNA viruses that have natural tropism for gut epithelial cells, immune cells, neurons, and cardiomyocytes. All strains of CVBs use the coxsackie–adenoviral receptor protein to gain entry into host cells (Figure).4 The coxsackie–adenoviral receptor molecule is a critical tight-junction protein important for cell–cell communication and for maintenance of cell membrane integrity. Interestingly, viruses such as CVB must use host signaling mechanisms, including tyrosine kinases such as . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
Eur J Heart FailHome page
S. Heymans, E. Hirsch, S. D. Anker, P. Aukrust, J.-L. Balligand, J. W. Cohen-Tervaert, H. Drexler, G. Filippatos, S. B. Felix, L. Gullestad, et al.
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
Eur J Heart Fail, February 1, 2009; 11(2): 119 - 129.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
M Comar, P D'Agaro, C Campello, A Poli, J P Breinholt III, J A Towbin, and M Vatta
Human herpes virus 6 in archival cardiac tissues from children with idiopathic dilated cardiomyopathy or congenital heart disease
J. Clin. Pathol., January 1, 2009; 62(1): 80 - 83.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
R. Dennert, H. J. Crijns, and S. Heymans
Acute viral myocarditis
Eur. Heart J., September 1, 2008; 29(17): 2073 - 2082.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Heymans
Myocarditis and heart failure: need for better diagnostic, predictive, and therapeutic tools
Eur. Heart J., June 1, 2007; 28(11): 1279 - 1280.
[Full Text] [PDF]